Reducing the risk of death by 35% Janssen Prostate Cancer Therapy Phase 3 Clinical Final Results...

Today, Janssen, a subsidiary of Johnson and Johnson, announced the final results of its prostate cancer therapy, Erleada, in phase 3 clinical trial TITAN.
trial results showed that Erleada was added to androgen deprivation therapy (ADT) in patients with metastatic desceptive prostate cancer (mCSPC), significantly improving the total survival of patients (OS) compared to placebo.
cancer is the second most common type of cancer in men among men between the two countries.
the past decade, the incidence of prostate cancer in China has been on the rise and is now the fifth most common cancer among chinese men.
metastatic de-sensitive prostate cancer (mCSPC) refers to prostate cancer that is still responsive to androgen deprivation therapy (ADT) and has spread to other parts of the body.
The de-trending endocrine treatment has long been the standard first-line treatment for advanced metastatic prostate cancer, but almost all of the prostate cancer (HSPC) that is sensitive to de-de-potential therapy eventually develops into desposed resistance (CRPC), and once developed into desopathic resistance, poor prognosmation, delayed entry into desopathic resistance is an important treatment strategy.
Erleada is a second-generation nonsteroidal androgen-inhibitor that blocks androgens and inhibits tumor growth.
has received FDA approval to treat mCSPC patients.
analysis showed that Erleada-ADT reduced the risk of death by 35% compared to ADT therapy at a time of nearly 4 years of medium follow-up time (HR=0.65, p-lt;0.0001).
phase 3 clinical trial, patients who were treated with a placebo after being blinded had the option of switching to the Erleada group.
the improvement in total survival reduced the risk of death by 48 percent when placebo patients were added to the Erleada group.
" TITAN's final analysis further confirms that Erleada therapy can extend total survival and provide clear long-term clinical benefits and identified safety characteristics for metastatic prostate cancer patients who are starting androgen deprivation therapy.
," said Dr. Kim Chi, an oncologist at the British Columbia Cancer Center (BC Cancer) in Canada and the principal director of TITAN's research.
: This article is intended to introduce medical and health research, not treatment options recommended.
if you need guidance on treatment options, visit a regular hospital.
resources: Janssen Announces Treatment with ERLEADA® Great Improved Survival in Patients with Metastatic Castration-Sensitive Prostate Cancer. Retrieved February 8, 2021, from